Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1588978 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $17.88Day −1.11%Mkt cap $1.0B1Y −66.8%Off 52W high −67.7%Vol (1Y) 63.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,218 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.6% of sh out |
| Days to cover4.9d |
| 13F net flow (QoQ)−5.33% |
| Top-10 13F concentration43.7% |
| Next report (est.)2026-07-30 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$322.0M |
| Earnings (TTM)-$102.5M |
| ROE−24.9% |
| Net margin−31.0% |
| ROIC−65.4% |
| Debt / equity0.14× |
| Sales growth 3Y60.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−43.2% |
| 1Y−66.8% |
| 3Y−48.1% |
| Since incept. (ann.)−13.4% |
Total return through 2026-07-29 · series begins 2021-09-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)63.9% |
| Ann. volatility (3Y)60.7% |
| Sharpe (1Y)−1.43 |
| Sharpe (3Y)−0.08 |
| Max drawdown (1Y)−69.1% |
| Max drawdown (3Y)−83.2% |
| Beta (3Y vs SPY)1.49 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.4M | $109M | 7.66% | +0.3% |
| T. Rowe Price Investment Management, Inc. | 3.3M | $82M | 5.75% | −10.5% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.1M | $77M | 5.43% | −0.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $61M | 4.25% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $60M | 4.21% | new |
| Chicago Capital, LLC | 2.2M | $54M | 3.80% | +81.4% |
| Prosight Management, LP | 1.9M | $49M | 3.42% | +40.9% |
| MACKENZIE FINANCIAL CORP | 1.7M | $43M | 3.02% | +9.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$0.56 | — | $83.1M | +20.2% |
| 2025-12-31 | 2026-02-25 | — | — | $76.4M | +11.9% |
| 2025-09-30 | 2025-11-04 | −$0.38 | — | $83.3M | +42.8% |
| 2025-06-30 | 2025-08-06 | −$0.35 | — | $79.2M | +48.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-30 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
US 88% · Non Us 12%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
